Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenerate AB

This article was originally published in Start Up

Executive Summary

By marrying gene therapy with medical device technology, Sweden's Xenerate AB believes it can make implantable vascular devices--artificial grafts and stents--capable of endothelialization, thus improving their biocompatibility and reducing the incidence of intimal hyperplasia, restenosis and other adverse effects.

You may also be interested in...



CliniGenetics SA

French start-up CliniGenetics SA has devised an integrated pharmacogenomics and bioinformatics technology platform to identify gene and protein targets associated with vascular diseases. The company hopes to use those targets to devise novel therapies and diagnostics.

Corgentech Inc.

Corgentech Inc. aims to avoid the problems that have thwarted viral and liposome-based gene delivery with a pressure-mediated delivery system. Its payload is decoys of transcription factors, the proteins that regulate gene expression. Corgentech's TF decoys are designed to bind with transcription factors, preventing normal DNA from burrowing in and activating its target gene.

Germany's Neuer Markt Shake Out

The Neuer Markt's fall from grace is more than a reflection of the global market slump. Having soared faster and higher than most other markets, Germany's growth exchange is now suffering the worst. And its recovery is likely to take longer.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel